Sartanos (Telmisartan) Driada Medical 20mg

Sartanos 20mg (Telmisartan)

Telmisartan is an antihypertensive agent and an angiotensin II receptor (type AT1) antagonist. It displays high affinity for the AT1 receptor subtype, displacing angiotensin II and reducing plasma aldosterone levels. Telmisartan acts specifically on the renin-angiotensin system without affecting other receptor subtypes or ion channels. It does not inhibit ACE (kininase II) and does not exhibit bradykinin-related side effects.

The use of telmisartan is attractive to athletes because it reduces left ventricular hypertrophy (LVH) and visceral fat. LVH, a response to intense weight training, can be amplified by steroid use. Reducing visceral fat is associated with a lower cardiovascular risk. Telmisartan acts as a harm reduction strategy, reducing overall mortality and cardiovascular disease risk.

Pharmacokinetics:

When taken orally, telmisartan is rapidly absorbed from the gastrointestinal tract with a bioavailability of 50%. Steady-state plasma concentrations reach after 3 hours, regardless of food intake. Telmisartan is highly protein bound (99.5%) and is metabolized by conjugation with glucuronic acid. The metabolites are pharmacologically inactive. The half-life of telmisartan is greater than 20 hours and it is excreted unchanged through the intestine.

How to use:

For adults, the recommended daily dose is 20-40 mg once daily, with some patients responding well to 20 mg/day. The dose can be increased up to 80 mg/day if necessary. No dose adjustments are necessary for patients with impaired renal function or elderly patients. Patients with impaired liver function should take a daily dose of 40 mg.

Athletes can use daily doses of 20–40 mg to reduce the risk of atherosclerosis, cardiovascular disease, and stroke in bodybuilders who use steroids and have prehypertension. Telmisartan may also improve HDL cholesterol levels, insulin sensitivity, mitochondrial activity, endothelial function, and cognitive function.

Effects:

• High blood pressure
• Reduction of cardiovascular risk
• Improved HDL cholesterol levels
• Increased insulin sensitivity
• Increased mitochondrial activity
• Improved endothelial function
• Improved cognitive function
• Reduction of left ventricular hypertrophy (LVH)
• Visceral fat reduction
• Reduction of water retention
• Decreased production of adrenaline which causes vasoconstriction of blood vessels

Side effects:

• Rare side effects of telmisartan may include:
• Vision variations
• Dizziness, fainting, or weakness
• Increased heart rate
• Large hives
• Pain when urinating or changes in urinary frequency
• Swelling in the hands, legs and feet

Profile:

• Half-life: 24 hours
• Frequency of intake: 1-2 times a day

Contraindications:

• Hypotension
• Pregnancy: Telmisartan tablets should be discontinued immediately upon diagnosis of pregnancy.

Conservation:

• Keep out of reach of children
• Store in a cool, dry place, away from direct sunlight
• Store at 25°C (77°F); temperatures between 15° and 30°C (59° and 86°F) are permitted.
• Do not use after the expiration date